Incurred Sample Reanalysis
Incurred Sample Reanalysis is a bioanalytical quality assurance process in which previously analyzed biological samples, containing analytes formed in vivo following administration of a drug to a subject, are reanalyzed to assess the reliability, reproducibility, and integrity of the original bioanalytical results.
35
Publications
775
Citations
265
Authors
105
Institutions
Publications per year
2017–2026
11
Variants
Isr
35
1–5 of 35
265
4
h-index
4
h-index
4
h-index
4
h-index
Pharmaceutical Product Development (United States), United States
3 publications · 141 citations
3
h-index
1–5 of 265
105

Pharmaceutical Product Development (United States)
Wilmington, United States
5 h-index
10 publications
360 citations
Bristol-Myers Squibb (United States)
New York, United States
5 h-index
17 publications
349 citations
Eli Lilly (United States)
Indianapolis, United States
4 h-index
10 publications
126 citations
Intertek (United States)
Houston, United States
4 h-index
6 publications
233 citations
Tandem Diabetes Care (United States)
San Diego, United States
4 h-index
7 publications
161 citations
PRA Health Sciences
Raleigh, United States
3 h-index
3 publications
141 citations
Novartis (Switzerland)
Basel, Switzerland
3 h-index
7 publications
289 citations
Amgen (United States)
Thousand Oaks, United States
3 h-index
16 publications
213 citations
1–8 of 105
BIO · 28 publications · 648 citations
14
h-index
AAPSJ · 2 publications · 28 citations
2
h-index
2 publications · 56 citations
2
h-index
1 publications · 11 citations
1
h-index
BMC · 1 publications · 15 citations
1
h-index
1–5